YS Biopharma Co., Ltd. (YS)
| Market Cap | 184.17M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 188.33M |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,366 |
| Open | 1.030 |
| Previous Close | 0.950 |
| Day's Range | 0.950 - 1.030 |
| 52-Week Range | 0.350 - 1.780 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 5.25 (+436.87%) |
| Earnings Date | May 28, 2024 |
About YS
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China. [Read more]
Financial Performance
In 2022, YS's revenue was 687.20 million, an increase of 36.63% compared to the previous year's 502.95 million. Losses were -421.46 million, 14.7% more than in 2021.
Financial numbers in CNY Financial StatementsAnalyst Forecast
According to one analyst, the rating for YS stock is "Buy" and the 12-month stock price forecast is $5.25.
News
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
GAITHERSBURG, Md. , May 7, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GAITHERSBURG, Md. , April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
GAITHERSBURG, Md. , April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
GAITHERSBURG, Md. , April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
GAITHERSBURG, Md. , April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
GAITHERSBURG, Md. , April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
GAITHERSBURG, Md. , April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
GAITHERSBURG, Md. , March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
GAITHERSBURG, Md. , Feb. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
GAITHERSBURG, Md. , Feb. 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.
NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ: YS) (the "Convening Shar...
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Appointment of New Directors
GAITHERSBURG, Md. , Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
GAITHERSBURG, Md. , Feb. 12, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces US$40 Million Private Placement Financing
GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
Shareholders of YS Biopharma Announce an Extraordinary General Meeting
BEIJING , Feb. 8, 2024 /PRNewswire/ -- Shareholders of YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
GAITHERSBURG, Md. , Jan. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Changes to its Board Committees
GAITHERSBURG, Md. , Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
GAITHERSBURG, Md. , Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023
GAITHERSBURG, Md. , Dec. 20, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target
GAITHERSBURG, Md. , Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces Receipt of Nasdaq Notice
GAITHERSBURG, Md. , Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md. , Sept. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
GAITHERSBURG, Md. , Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd.